Preimplantation Genetic Diagnosis Market Overview, Analysis, Impact of Coronavirus (COVID-19) Pandemic, forecast 2020-2027

 

Preimplantation Genetic Diagnosis

Patients who choose in vitro fertilisation, Preimplantation Genetic Diagnosis is performed to test for aneuploidy in situations with poor prognosis. It is also useful in the identification of inherited single gene illnesses, X-linked diseases, and, more recently, late-onset diseases.

Preimplantation Genetic Diagnosis is a procedure for discovering genetic problems in IVF embryos before they become pregnant. PGD is the process of testing embryos for genetic abnormalities. Current post-conception diagnostic methods are being replaced by PGD. Preimplantation Genetic Diagnosis is a technology used in IVF genetic testing that allows for a more thorough analysis of embryos than just their appearance. By completing embryo genetic testing, PGD considerably decreases the risks of generating unhealthy embryos, which is a major driving factor for market expansion. Furthermore, it improves the odds of having a healthy pregnancy. Furthermore, variables such as an increase in the usage of alcohol, drugs, smoking, and a poor diet; an increase in stress; an increase in environmental pollutants; and an increase in hormone-related health issues have all raised the risk.

The global Preimplantation Genetic Diagnosis Market is estimated to account for US$ 53.5 Mn in terms of value in 2020 and is expected to reach US$ 81.6 Mn by the end of 2027.

The usage of IVF has increased, favourably impacting market growth. Furthermore, benefits such as the development of saviour siblings and the increased adoption of assisted reproductive technology (ART) in underdeveloped nations are projected to boost the PGD industry. Furthermore, an increase in the risk of catastrophic genetic, hereditary, and chromosomal illnesses such Duchenne muscular dystrophy, down syndrome, cystic fibrosis, triploidy, and thalassemia encourages patients to choose PGD, expanding the market size for preimplantation genetics diagnosis.

According to the Centers for Disease Control and Prevention (CDC), 330,773 assisted reproductive technology (ART) cycles were done across 448 reporting clinics in 2019, resulting in 77,998 live births. Furthermore, ART use has nearly risen in the previous decade, accounting for around 2.1 percent of all children born in the United States each year. Pre-implantation genetic diagnostics for monogenic or single-gene diseases (PGT-M) can also be used to avert more than 600 genetic problems, according to the UK's Human Fertilization and Embryology Authority.

Furthermore, according to Statistics Canada, Canada's fertility rate fell from 1.47 children per woman in 2019 to 1.40 children per woman in 2020, a new low. Furthermore, in 2020, Canada saw the lowest number of births and a 3.6 percent fall in births, the worst drop since 2006. Many nations throughout the world are experiencing a decrease in fertility rates. These characteristics have a beneficial impact on the market for Preimplantation Genetics Diagnosis.

Impact of Covid-19 on Preimplantation Genetic Diagnosis Market

The new coronavirus has swiftly spread throughout several nations and regions, wreaking havoc on people's lives and the community as a whole. It originated as a human health issue and has since evolved into a major danger to global trade, commerce, and finance. The COVID-19 pandemic raised the relevance of government healthcare institutions, resulting in a rise in global healthcare spending. COVID-19 incidences are also predicted to decline in the future as the vaccination becomes available. As a result, businesses that provide PGD have reopened. By the beginning of 2022, the market had recovered. To respond to urgent situations and build new working techniques post-pandemic, companies focus on protecting their employees, operations, and supply networks. Moreover, financial slowdown caused by COVID-19 negatively influenced the preimplantation genetics diagnosis market growth.